In the second part and conclusion, a spotlight on the mass marketing of the synthetic opioid fentanyl examines the connections between drug manufacturers and government policy. Video of sales retreats and promotional material reveals a deep cynicism among company employees and a disregard for the widespread, nefarious corporate practices.

This series is a searing indictment of Big Pharma and the political operatives and government regulations that enable over-production, reckless distribution and abuse of synthetic opiates. Exploring the origins, extent and fallout of one of the most devastating public health tragedies of our time, with half a million deaths from overdoses this century alone, the film reveals that America's opioid epidemic is not a public health crisis that came out of nowhere.
In the first part, a look at how Purdue Pharma worked with the FDA to get OxyContin approved for wider use, promoting the highly profitable pain medication's safety without sufficient evidence, and creating a campaign to redefine pain and how it's treated.

Valeant Pharmaceuticals was a multinational specialty pharmaceutical company based in Canada. It grew rapidly through a series of mergers and acquisitions under the leadership of J. Michael Pearson. The company was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs, which led to an investigation by the U.S. Securities and Exchange Commission and caused its stock price to plummet more than 90 percent from its peak while its debt surpassed $30 billion.
Wall Street short-sellers exposed a scam that regulators overlook: how Big Pharma gouges patients in need of life-saving drugs.

Director Chris Bell turns his camera on the abuse of prescription drugs and, ultimately, himself. After witnessing friends and relatives face tragedy as they become addicted to prescription drugs, Bell sets out to explore the goals of pharmaceutical companies and doctors in this ever-growing market, and asks how they are any different from back-alley drug-pushers. His journey leads to experts on the nature of addiction in our culture, as well as to pharmaceutical whistleblowers that testify to the solely dollar-driven aims of pharmaceutical companies.